BioArctic AB (publ) (STO:BIOA.B)
311.00
-6.20 (-1.95%)
Nov 2, 2026, 5:24 PM CET
BioArctic AB Revenue
BioArctic AB had revenue of 247.53M SEK in the quarter ending June 30, 2026, a decrease of -36.88%. This brings the company's total for the last twelve months to 1.00B, down -46.09% year-over-year. In the year 2025, BioArctic AB had annual revenue of 2.00B with 676.80% growth. That makes BioArctic AB the 22,524th largest company in the world by revenue and 285th in Sweden.
Revenue (ttm)
1.00B
Revenue Growth
-46.09%
P/S Ratio
28.07
Revenue / Employee
6.68M
Employees
150
Market Cap
27.59B
Revenue by Geography
- North America 1.32B 66.3%
- Asia 593.78M 29.7%
- Europe 80.15M 4.0%
- Others 270.00K 0.0%
Fiscal year ended Dec 31, 2025 See the full BioArctic AB breakdown
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 2.00B | 1.74B | 676.80% |
| Dec 31, 2024 | 257.35M | -358.64M | -58.22% |
| Dec 31, 2023 | 616.00M | 386.56M | 168.49% |
| Dec 31, 2022 | 229.43M | 203.77M | 794.02% |
| Dec 31, 2021 | 25.66M | -39.54M | -60.64% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. It does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Camurus AB | 2.27B |
| Saniona AB | 424.56M |
| Hansa Biopharma AB | 189.46M |
| Genovis AB (publ.) | 135.89M |
| Egetis Therapeutics AB | 66.00M |
| Medivir AB | 8.71M |
| Vicore Pharma Holding AB | 3.99M |
| Flerie AB | 2.60M |
BioArctic AB News
- 3 days ago - BioArctic's Nomination Committee appointed - PRNewsWire
- 3 days ago - New clinical data on lecanemab to be presented at CTAD conference 2026 - PRNewsWire
- 4 days ago - BioArctic Royalty Income Rises 74% As Leqembi Sales Reach JPY 32.2 Bln - Nasdaq
- 5 days ago - Sales of Leqembi® totaled 32.2 billion yen in the third quarter 2026 - PRNewsWire
- 5 weeks ago - First patient treated with Leqembi® (lecanemab) in Sweden - PRNewsWire
- 6 weeks ago - Leqembi® Pen subcutaneous formulation approved in Japan - PRNewsWire
- 2 months ago - Number of shares and votes in BioArctic AB (publ) as of August 31, 2026 - PRNewsWire
- 2 months ago - BioArctic AB Earnings Call Transcript: Q2 2026 - Transcripts